Literature DB >> 21204800

Bone resorption in syndromes of the Ras/MAPK pathway.

D A Stevenson1, E L Schwarz, J C Carey, D H Viskochil, H Hanson, S Bauer, H-Y Cindy Weng, T Greene, K Reinker, J Swensen, R J Chan, F-C Yang, L Senbanjo, Z Yang, R Mao, M Pasquali.   

Abstract

Disorders of the Ras/mitogen-activated protein kinase (MAPK) pathway have an overlapping skeletal phenotype (e.g. scoliosis, osteopenia). The Ras proteins regulate cell proliferation and differentiation and neurofibromatosis type 1 (NF1) individuals have osteoclast hyperactivity and increased bone resorption as measured by urine pyridinium crosslinks [pyridinoline (Pyd) and deoxypyridinoline (Dpd)]. Pyd and Dpd are hydroxylysine-derived crosslinks of collagen found in bone and cartilage and excreted in the urine. Dpd is most abundant in bone. The aim of this study was to evaluate if other syndromes of the Ras/MAPK pathway have increased bone resorption, which may impact the skeletal phenotype. Participants were individuals with Noonan syndrome (n = 14), Costello syndrome (n = 21), and cardiofaciocutaneous (CFC) syndrome (n = 14). Pyridinium crosslinks from two consecutive first morning urines were extracted after acid hydrolysis and analyzed by high performance liquid chromatography. Three separate analyses of covariance were performed to compare Pyd, Dpd, and Dpd/Pyd ratio of each group to controls after controlling for age. Data were compared to 99 healthy controls. The Dpd and the Dpd/Pyd ratio were elevated (p < 0.0001) in all three conditions compared to controls suggesting that collagen degradation was predominantly from bone. The data suggest that the Ras/MAPK signal transduction pathway is important in bone homeostasis.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21204800      PMCID: PMC3246507          DOI: 10.1111/j.1399-0004.2010.01619.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  55 in total

1.  Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.

Authors:  D Uebelhart; E Gineyts; M C Chapuy; P D Delmas
Journal:  Bone Miner       Date:  1990-01

2.  The Ullrich-Noonan syndrome (Turner phenotype).

Authors:  J J Nora; A H Nora; A K Sinha; R D Spangler; H A Lubs
Journal:  Am J Dis Child       Date:  1974-01

Review 3.  Noonan syndrome.

Authors:  J E Allanson
Journal:  J Med Genet       Date:  1987-01       Impact factor: 6.318

4.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Authors:  Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2002-05-01       Impact factor: 11.025

5.  Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.

Authors:  P D Delmas; A Schlemmer; E Gineyts; B Riis; C Christiansen
Journal:  J Bone Miner Res       Date:  1991-06       Impact factor: 6.741

6.  Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases.

Authors:  S P Robins; D Black; C R Paterson; D M Reid; A Duncan; M J Seibel
Journal:  Eur J Clin Invest       Date:  1991-06       Impact factor: 4.686

7.  Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography.

Authors:  D R Eyre; T J Koob; K P Van Ness
Journal:  Anal Biochem       Date:  1984-03       Impact factor: 3.365

8.  Costello syndrome: orthopaedic manifestations and functional health.

Authors:  Walid K Yassir; Brian E Grottkau; Michael J Goldberg
Journal:  J Pediatr Orthop       Date:  2003 Jan-Feb       Impact factor: 2.324

9.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

10.  Orthopaedic manifestations of neurofibromatosis in children: an update.

Authors:  Michael G Vitale; Abhijit Guha; David L Skaggs
Journal:  Clin Orthop Relat Res       Date:  2002-08       Impact factor: 4.176

View more
  27 in total

1.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

2.  Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.

Authors:  Z J Zhai; H W Li; G W Liu; X H Qu; B Tian; W Yan; Z Lin; T T Tang; A Qin; K R Dai
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Sophocarpine attenuates wear particle-induced implant loosening by inhibiting osteoclastogenesis and bone resorption via suppression of the NF-κB signalling pathway in a rat model.

Authors:  Chen-He Zhou; Zhong-Li Shi; Jia-Hong Meng; Bin Hu; Chen-Chen Zhao; Yu-Te Yang; Wei Yu; Ze-Xin Chen; Boon Chin Heng; Virginia-Jeni Akila Parkman; Shuai Jiang; Han-Xiao Zhu; Hao-Bo Wu; Wei-Liang Shen; Shi-Gui Yan
Journal:  Br J Pharmacol       Date:  2018-02-14       Impact factor: 8.739

4.  Valosin-containing protein and neurofibromin interact to regulate dendritic spine density.

Authors:  Hsiao-Fang Wang; Yu-Tzu Shih; Chiung-Ya Chen; Hsu-Wen Chao; Ming-Jen Lee; Yi-Ping Hsueh
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

5.  Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?

Authors:  Kiran S Choudhry; Monica Grover; Alyssa A Tran; E O'Brian Smith; Kenneth J Ellis; Brendan H Lee
Journal:  Mol Genet Metab       Date:  2012-04-11       Impact factor: 4.797

6.  Low-intensity pulsed ultrasound inhibits RANKL-induced osteoclast formation via modulating ERK-c-Fos-NFATc1 signaling cascades.

Authors:  Jiahong Meng; Jianqiao Hong; Chenchen Zhao; Chenhe Zhou; Bin Hu; Yute Yang; Guangyao Jiang; Sihao Li; Zhongli Shi; Xunzi Cai; Shigui Yan
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

7.  Genkwanin Prevents Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone Loss.

Authors:  Xin Fu; Xiaochen Sun; Chenxi Zhang; Nanning Lv; Huan Guo; Chunlei Xing; Juan Lv; Jiwen Wu; Xiaoli Zhu; Mingming Liu; Li Su
Journal:  Front Nutr       Date:  2022-06-23

8.  Craniofacial and dental development in Costello syndrome.

Authors:  Alice F Goodwin; Snehlata Oberoi; Maya Landan; Cyril Charles; Jessica C Massie; Cecilia Fairley; Katherine A Rauen; Ophir D Klein
Journal:  Am J Med Genet A       Date:  2014-03-25       Impact factor: 2.802

9.  Erk1 positively regulates osteoclast differentiation and bone resorptive activity.

Authors:  Yongzheng He; Karl Staser; Steven D Rhodes; Yaling Liu; Xiaohua Wu; Su-Jung Park; Jin Yuan; Xianlin Yang; Xiaohong Li; Li Jiang; Shi Chen; Feng-Chun Yang
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

10.  Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation.

Authors:  Xiangying Kong; Wenbin Wu; Yue Yang; Hongye Wan; Xiaomin Li; Michun Zhong; Hongyan Zhao; Xiaohui Su; Shiwei Jia; Dahong Ju; Na Lin
Journal:  J Transl Med       Date:  2015-03-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.